Skip to main content

hemangeol

Generic: PROPRANOLOL HYDROCHLORIDE

hemangeol: sourced relationships with 1 company · 1 FDA decision.

hemangeol evidence translation

What we can confirm

What it means

Source-backed records connect hemangeol to ETON; that link alone does not prove the drug works.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

How could hemangeol → ETON affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

Dated Pipeline Records (1)
CompanyDated record stage
Eton Pharmaceuticals, Inc. (ETON)
Reported 2014-03-14 · Current development: unknownSource
Approved
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE HEMANGEOL oral solution contains the beta-adrenergic blocker propranolol hydrochloride and is indicated for the treatment of proliferating infantile hemangioma requiring systemic therapy. HEMANGEOL oral solution is a beta-adrenergic blocker indicated for the treatment of proliferating infantile hemangioma requiring systemic therapy. ( 1 )(ETON)FDA ↗
NDA205410Type 5 - New Formulation or New ManufacturerOrphan DrugStandardOralSolution

Frequently asked questions

Which companies have sourced relationships with hemangeol?

hemangeol has dated SEC/FDA relationship records for Eton Pharmaceuticals, Inc..

What is hemangeol's latest FDA decision?

The most recent tracked FDA decision for hemangeol is Approval for 1 INDICATIONS AND USAGE HEMANGEOL oral solution contains the beta-adrenergic blocker propranolol hydrochloride and is indicated for the treatment of proliferating infantile hemangioma requiring systemic therapy. HEMANGEOL oral solution is a beta-adrenergic blocker indicated for the treatment of proliferating infantile hemangioma requiring systemic therapy. ( 1 ), dated March 14, 2014.